

## DAFTAR PUSTAKA

- Ananworanich, J. et al., 2005. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine , efavirenz or both drugs. *AIDS*, 19(September 2004), pp.185–192.
- Boehringer Ingelheim, 2005. *Viramune* ® ( *nevirapine* ) *Tablets & Oral Suspension*, Ridgefield.
- Brunton, L.L., Lazo, J.S. & Parker, K.L., 2006. *Goodman & Gilman's The Pharmacology Basis of Therapeutics* 7th ed., New York: McGraw-Hill.
- Carr, D.F. et al., 2013. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. *Clinical Infectious Diseases*, 56(9), pp.1330–1339.
- Commission, N.A., 2013. *Global AIDS Response Progress Reporting*, Jakarta.
- Dickinson, L. et al., 2014. Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from. *Antimicrobial Agents and Chemotherapy*, 58(2), pp.706–712.
- Fajar, E., 2013. *Hubungan Antara Stadium Klinis, Viral Load Dan Jumlah CD4 Pada Pasien Human Immunodeficiency Virus (HIV)/Acquired Immuno Deficiency Syndrome (AIDS) Di RSUP Dr. Kariadi Semarang*. Universitas Diponegoro.
- Gillis, S., Robert Kozak & Michael Durante, 1981. Immunological Studies of Aging. *Journal Clinical Investigation*, 67(April), pp.937–942.
- Harding, P. & Pinsky, L., 2009. *The Columbia University Handbook on HIV and AIDS* C. Heffer, ed., New York: Columbia University. Available at: [https://health.columbia.edu/system/files/content/healthpdfs/MS/GHAP\\_HIV\\_Aids\\_Handbook.pdf](https://health.columbia.edu/system/files/content/healthpdfs/MS/GHAP_HIV_Aids_Handbook.pdf).
- Havlir, D. et al., 1995. High-Dose Nevirapine : Safety , Pharmacokinetics , and Antiviral Effect in Patients with Human Immunodeficiency Virus Infection. *The Journal of Infectious Diseases*, 171, pp.537–545.
- Inkeles, B.Y.B. et al., 1977. Immunological Studies Of Aging. *The Journal Of Experimental Medicine*, 145, pp.1176–1187.
- Ivon, H., 2011. *Beberapa Faktor Yang Berpengaruh Terhadap Kejadian Malaria Pada Anak*. Universitas Diponegoro.
- Kappelhoff, B.S. et al., 2005. Are adverse events of nevirapine and efavirenz related to plasma concentrations ? *Antiviral Therapy*, 10, pp.489–498.

- Katzung, B.G., Masters, S.B. & Trevor, A.J., 2012. *Basic & Clinical Pharmacology* 12th ed., The McGraw- Hill Companies, Inc.
- Kemenkes, 2014. Infodatin : Pusat Data dan Informasi Kementerian Kesehatan RI. , pp.1–6.
- Kemenkes, 2011. *Pedoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral*, Kementerian Kesehatan RI- Ditjen Pengendalian Penyakit dan Penyehatan Lingkungan.
- Khan, D.A. & Solensky, R., 2010. Drug allergy. *Journal Allergy Immunology*, 127(3), pp.126–138.
- Kiertiburanakul, S. et al., 2009. A Model and Risk Score for Predicting Nevirapine-Associated Rash among HIV-infected Patients : In Settings of Low CD4 Cell Counts and Resource. *The Open AIDS Journal*, 3, pp.24–30.
- Klein, S.L. & Flanagan, K.L., 2016. Sex differences in immune responses. *Nature Publishing Group*. Available at: <http://dx.doi.org/10.1038/nri.2016.90>.
- Longo, D. et al., 2012. *Harrison 's Principles of Internal Medicine* 18th ed., New York: Mc Graw Hill.
- Meier, A. et al., 2009. Sex differences in the Toll-like receptor – mediated response of plasmacytoid dendritic cells to HIV-1. *Nature Publishing Group*, 15(8), pp.1–6. Available at: <http://dx.doi.org/10.1038/nm.2004>.
- Milpied-Homsy, B., Moran, E.M. & Phillips, E.J., 2015. Antiviral Drug Allergy. *Immunol Allergy Clin North Am*, 34(3), pp.645–662.
- Munthali, C. et al., 2014. Diagnostic accuracy of the WHO clinical staging system for defining eligibility for ART in sub-Saharan Africa : a systematic review and meta-analysis.
- Pavlos, R. et al., 2015. T Cell–Mediated Hypersensitivity Reactions to Drugs. *Annu Rev Med*, 14(66), pp.439–454.
- Phillips, E.J. & Mallal, S.A., 2010. Pharmacogenetics of drug hypersensitivity Review. *Future Medicine*, 11(7), pp.973–987.
- Pichler, W.J. et al., 2002. Cellular and Molecular Pathophysiology of Cutaneous Drug Reactions. *AMJ Clinical Dermatology*, 3(4), pp.229–238.
- Pichler, W.J., 2007. Drug Hypersensitivity Reactions: Classification and Relationship to T-Cell Activation. *Basel Karger*, pp.168–189.
- Rockstroh, J.K., Hoffmann, C. & et.al, 2012. *Hiv 2012/2013*, Hamburg: Medizin Fokus Verlag. Available at: [www.hivbook.com](http://www.hivbook.com).

- Saltzman, R.L. & Peterson, P.K., 2016. Immunodeficiency of the Elderly. *Reviews of Infectious Diseases*, 9(6), pp.1127–1139.
- Sastroasmoro, S. & Ismael, S., 2011. *Dasar-Dasar Metodologi Penelitian Klinis* 4th ed., Jakarta: CV Agung Seto.
- Schentag, J.J., 2001. Sex Differences in Nevirapine Rash. *Clinical Infectious Diseases*, 33, pp.2096–2097.
- Sehcal, V.N. & Gangwani, O.M.P., 1987. Fixed Drug Eruption. *International Journal Of Dermatology*, 26(2), pp.67–75.
- Shubber, Z. et al., 2013. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. *AIDS*, 27(9), pp.1403–12.
- Sukasem, C., 2014. Review article Pharmacogenomics of drug-induced hypersensitivity reactions: challenges , opportunities and clinical implementation. *Asian Pac J Allergy Immunol*, 32, pp.111–123.
- Tansuphaswadikul, S., Aung, S.E., Phonrat, B., Kaewkungwal, J., et al., 2007. Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4 count. *Asian Pacific Journal of Allergy and Immunology*, 25(2–3), pp.147–154.
- Tansuphaswadikul, S., Aung, S.E., Phonrat, B. & Kaewkungwal, J., 2007. Predisposing Factors for Nevirapine Toxicity among AIDS Patients with Low Baseline CD4 Count. *Asian Pacific Journal Of Allergy And Immunology*, 25, pp.147–154.
- The Joint United Nations Programme on HIV/AIDS UNAIDS, 2015. *Fact Sheet 2015*, New York.
- Thong, B. & Tan T.C., 2011. Epidemiology and risk factors for drug allergy. *Br J Clin Pharmacol*, 71, pp.684–700.
- Tseng, Y. et al., 2014. International Journal of Infectious Diseases Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan. *International Journal of Infectious Diseases*, 29, pp.12–17. Available at: <http://dx.doi.org/10.1016/j.ijid.2014.08.012>.
- Tsuchiya, N. et al., 2014. Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand : a cohort study. *BMC Infectious Diseases*, 14(565), pp.1–8.
- WHO, 2005. *Interim Who Clinical Staging Of HIV/AIDS And HIV/AIDS Case Definitions For Surveillance*, Geneva.

WHO, 2004. Public health Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *The Lancet*, 363, pp.157–163.

Wit, F.W.N.M. et al., 2008. Discontinuation of Nevirapine Because of Hypersensitivity Reactions in Patients with Prior Treatment Experience , Compared with Treatment- Naive Patients : The ATHENA Cohort Study. *Clinical Infectious Diseases*, 46, pp.933–940.

Wolff, K., Goldsmith, L.A. & Katz, S.I., 2008. *Fitzpatrick's Dermatology in General Medicine* 7th ed., New York: Mc Graw Hill.